The global chemotherapy induced anemia market is anticipated to be worth US$ 2.25 Bn in terms of revenue in 2022. The market is projected to expand at a CAGR of 7.2% to reach a market size of US$ 4.30 Bn by 2032.
“Innovations in the field of chemotherapy-induced anemia, rising government initiatives, and technologically advanced healthcare infrastructure to set the tone for chemotherapy-induced anemia market.”
A reduction in the total number of red blood cells or hemoglobin in the blood is a sign of anemia. The amount of oxygen delivered to the body's cells will be insufficient if there are not enough or malformed red blood cells. Anemia can take many distinct forms, including anemia brought on by blood loss, anemia brought on by the breakdown of red blood cells, anemia brought on by inadequate or flawed red blood cell formation, etc.
The most prevalent and chronic hematological abnormality among patients with oncology diseases is anemia. Chemotherapy is primarily responsible for chemotherapy-induced anemia, which also considerably worsens fatigue and quality of life. Chemotherapy often slows or restricts the course of treatment. Mouth sores, altered tastes, or nausea are some of the most prominent symptoms, all of which restrict nutrient intake necessary for the development of red blood cells.
| Attributes | Details |
|---|---|
| Chemotherapy Induced Anemia Market CAGR | 7.2% |
| Chemotherapy Induced Anemia Market (2022) | US$ 2.25 Billion |
| Chemotherapy Induced Anemia Market (2032) | US$ 4.30 Billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Chemotherapy is largely responsible for chemotherapy-induced anemia, which further exacerbates fatigue and affects livability negatively. Anemia is a significant complication that complicates the course of cancer. Chemotherapy frequently delays or inhibits the course of treatment. Because of this, there is an increasing preference for chemotherapy-induced anemia. Increasing understanding of the significance of early detection and intervention. The rising prevalence of cancer, expanding requirement for biopharmaceuticals, and rising preference for homecare settings are all propelling the growth in this industry.
One of the primary reasons expected to fuel the growth of the global market for chemotherapy-induced anemia is the prevalence of cancer and anemia in geriatric individuals. Demand for chemotherapy induced anemia is growing due to bone marrow invasion and growth in systemic inflammation disorder.
The difficulties in treating anemic patients have given rise to a unique class of medicines, such as HIF-PH inhibitors, that possess the potential to transform the current anemia therapy approach. Furthermore, with the introduction of novel IV iron supplements, anemia has become more controllable, fueling the expansion of the chemotherapy induced anemia market.
Other significant drivers expected to drive market expansion throughout the projected period are advancement and innovation, technical advancements, government incentives,
and improvements in pipeline items. The existence of advantageous reimbursement policies is expected to generate profitable opportunities for market expansion in the approaching years.
The leading competitors in the chemotherapy induced anemia market are spending on research and development of technologically advanced novel solutions, which would lead to higher use of chemotherapy induced anemia products in both developed and developing nations worldwide. They are also designing and manufacturing cost-effective as well as high-quality drugs and solutions to capitalize on the vast untapped prospects in emerging nations. This is evident in the increasing number of new drugs approved.
Manufacturers provide Ferric carboxymaltose, a kind of iron complexing agent. It has been utilized to diagnose anemia disorders induced by chemotherapy, radiation therapy, and blood transfusion. Chemotherapy induced anemia is also known as CIA or cytological immunodeficiency anemia (CID). The medicine works by eliminating extra iron from the body, which increases hemoglobin supply by decreasing its binding to ferritin.
Market participants also provide PEGylated erythropoietin (EPO), a lipid-soluble version of the hormonal erythropoietin that increases mortality in cancer sufferers. To treat chemotherapy-induced anemia, EPO is now utilized in conjunction with other medicines. To meet the demand for cancer treatment, producers supply epoetin zeta, which is used to treat anemia caused by chemotherapy and radiation therapy.
Principal Consultant
The prevalence of cancer and anemia in elderly patients is one of the key factors driving the growth of the global market for chemotherapy-induced anemia. Other major factors driving the market include bone marrow invasion, an increase in chronic inflammatory diseases, an increase in pipeline items, technological developments, and reimbursement policies.
The development of anemia as a side effect of cancer treatment and an increase in the number of causes of anemia in cancer patients are additional factors that are anticipated to fuel the expansion of the global market for chemotherapy-induced anemia.
The development of technology in the identification of targets for chemotherapy-induced myelosuppression from various human organs, including bone marrow, and blood systems, including peripheral blood, is one of the market drivers. In addition, one of the key reasons boosting the market is awareness regarding chemotherapy-induced anemia and its need for early detection, prevention, and fast treatment.
The chemotherapy-induced anemia market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America is the leading region in the global chemotherapy-induced anemia market due to the increasing availability of a number of chemotherapy agents and advanced healthcare infrastructure.
Apart from North America, the European chemotherapy-induced anemia market is also expected to display lucrative growth in the projected years due increasing prevalence of cancer and anemia among the geriatric population.
The East Asian region is predicted to show lucrative growth owing to the rising medical tourism and the large patient pool suffering from anemia.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Astellas Pharma Inc., Blausen Medical, Dr. Reddy's Laboratories Ltd., Elsevier Inc., F. Hoffmann-La Roche Ltd, FibroGen, Inc., GlaxoSmithKline PLC, Healio, Johnson & Johnson, Karger AG, Novartis AG, Pfizer Inc.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 7.2% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered | Range of Anemia, Treatment Type, Drug Type, End User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Players | Astellas Pharma Inc.; Blausen Medical; Dr. Reddy's Laboratories Ltd.; Elsevier Inc.; F. Hoffmann-La Roche Ltd; FibroGen, Inc.; GlaxoSmithKline PLC; Healio; Johnson & Johnson; Karger AG; Novartis AG; Pfizer Inc. |
| Customization | Available Upon Request |
The market is likely to register a CAGR of 7.2% through 2032.
The market is currently valued at US$ 2.25 Bn in 2022.
The market is likely to grow to a valuation of US$ 4.30 Bn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Healthcare Insights
View Reports
Chemotherapy Induced Anemia Market
